Kestra Medical director granted 8,300 RSUs

Reilly Kevin C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Reilly Kevin C reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies director Kevin C. Reilly received an equity award of 8,300 common shares in the form of restricted stock units. The RSUs were granted at no cash cost and each unit represents one common share. All 8,300 RSUs will vest on September 4, 2026, if he continues serving through that date, at which point he would hold 8,300 vested common shares from this award.

Insider Trade Summary

Grant/Award: 8,300 shares

Grant/Award 1 txn

Insider Reilly Kevin C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	8,300	$0.00	$0.00

Holdings After Transaction: Common Shares — 8,300 shares (Direct)

Footnotes (1)

1. F1. The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KMTS director Kevin C. Reilly report on this Form 4?

Director Kevin C. Reilly reported receiving an award of 8,300 restricted stock units of Kestra Medical Technologies. Each RSU represents one common share and was granted at no cash cost, reflecting compensation rather than an open‑market purchase or sale.

How many Kestra Medical (KMTS) shares are covered by Kevin C. Reilly’s RSU grant?

The grant covers 8,300 restricted stock units, each tied to one common share of Kestra Medical Technologies. If all conditions are met and the RSUs vest, Reilly would receive 8,300 common shares from this award alone.

When do Kevin C. Reilly’s KMTS restricted stock units vest?

The 8,300 restricted stock units are scheduled to vest on September 4, 2026, subject to Kevin C. Reilly’s continued service through that date. Vesting means the units convert into common shares that he then owns outright as part of his compensation.

Did Kevin C. Reilly buy or sell KMTS shares in the market in this filing?

No open‑market buy or sell was reported. The Form 4 shows a grant of 8,300 restricted stock units as compensation, with a stated price of zero per share, rather than a purchase or sale on the public market.

What are restricted stock units (RSUs) in the context of KMTS’s Form 4?

Restricted stock units are a form of equity compensation that convert into shares at vesting. In this case, each RSU entitles Kevin C. Reilly to one Kestra Medical common share if he remains in service through the September 4, 2026 vesting date.

How many Kestra Medical (KMTS) shares does Kevin C. Reilly hold after this RSU grant?

Following the reported transaction, Kevin C. Reilly’s position from this award is 8,300 common shares underlying the RSUs. These shares will be issued upon vesting, assuming he continues to meet the service condition through September 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reilly Kevin C

(Last) (First) (Middle)

C/O ALLY BRIDGE GROUP

430 PARK AVENUE 12TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/11/2026		A		8,300	A	(1)	8,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

	/s/ Traci S. Umberger as attorney-in-fact for Kevin C. Reilly	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.